LIGHTPATH TECHNOLOGIES INC

**Signal Note: Driehaus Capital Initiates $19.9M Position in LightPath Technologies** LightPath is an optical materials and imaging solutions company, not a drug developer—this appears to be a capital allocation signal toward the broader optics/photonics sector rather than a biotech-specific catalyst. The $19.9M position (representing ~4.4% of Driehaus' biotech allocation at typical fund sizing) suggests conviction in LightPath's medical imaging or surgical visualization applications, though no near-term clinical or regulatory catalysts are evident from the company's pipeline. Investors should clarify whether this reflects conviction in LightPath's core business fundamentals or repositioning within Driehaus' portfolio.